Earnings
Ultragenyx Cuts About 20% Of Staff To 1,000 After Angelman Trial Miss, Targets 2027 Profit
The drugmaker will end its Wilson disease program, hold 2027 R&D below $350 million and says two voucher sales remove any need to raise cash.
RARE
Ultragenyx Pharmaceutical (RARE) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Ultragenyx To Cut About 20% Of Staff, Wind Down GTX-102 Studies And Drop UX701
The rare-disease drugmaker reaffirmed 2027 profitability and said the cuts should lower 2027 R&D spending by at least 50% versus 2025.
SEC Filings
Madison Avenue Group Reports 6.4% Passive Stake In Ultragenyx, 6,307,798 Shares
A New York group tied to Eli Samaha filed a passive ownership disclosure on Ultragenyx, which closed at $16.02 on Tuesday.
SEC Filings
Ultragenyx Settles DOJOLVI Patent Suit, Licensing Navinta's Generic From January 1, 2033
The license is royalty-free and moves to July 1, 2033 if pediatric exclusivity is granted; other generic-filer suits remain pending.
Deals
Ultragenyx Agrees To Sell Pediatric Disease Review Voucher For $203 Million In Cash
The drugmaker's 8-K ties the voucher to the FDA's September 17 approval of FAYUVI; a separate report cites $210 million.
Deals
Ultragenyx Agrees To Sell FDA Priority Review Voucher For $210 Million Cash, 8-K Says
The drugmaker owes the NIH 20% of gross proceeds, and the sale still needs antitrust waiting-period clearance before it closes.